Imiquimod hydrochloride
Imiquimod hydrochloride is an immune response modifier that acts as a toll-like receptor 7 agonist and is commonly used topically to treat warts on the skin of the genital and anal areas.
| Physical Appearance | A solid |
| Storage | Store at -20°C |
| M.Wt | 276.76 |
| Cas No. | 99011-78-6 |
| Formula | C14H17ClN4 |
| Solubility | ≥3.59 mg/mL in EtOH with ultrasonic; ≥5.54 mg/mL in DMSO with gentle warming and ultrasonic; ≥7.34 mg/mL in H2O with ultrasonic |
| Chemical Name | 1-isobutyl-1H-imidazo[4,5-c]quinolin-4(5H)-imine hydrochloride |
| SDF | Download SDF |
| Canonical SMILES | CC(CN1C=NC2=C1C3=CC=CC=C3NC2=N)C.Cl |
| Shipping Condition | Small Molecules with Blue Ice, Modified Nucleotides with Dry Ice. |
| General tips | We do not recommend long-term storage for the solution, please use it up soon. |
| Cell experiment:[1] | |
|
Cell lines |
Thioglycollate-elicited peritoneal cells from wild-type (C57BL/6) and MyD88-deficient mice |
|
Reaction Conditions |
101 ~ 104 nM imiquimod for 24 h incubation |
|
Applications |
Imiquimod increased TNF-α and IL-12p40 production in IFN-γ-treated murine peritoneal macrophages in a concentration- and MyD88-dependent manner. |
| Animal experiment:[2] | |
|
Animal models |
Female Hartley guinea pigs, 400 ~ 500 g |
|
Dosage form |
5 mg/kg Administered intravaginally every 12 h for five days beginning 12 h after genital HSV-2 inoculation |
|
Applications |
Imiquimod (5 mg/kg, intravaginally, twice daily) reduced vaginal viral titer and lesion formation in a guinea pig model of genital HSV-2 infection. Imiquimod exhibited potent anti-HSV activity in vivo due to cytokine induction and enhancement of cell-mediated responses. |
|
Note |
The technical data provided above is for reference only. |
|
References: 1. Hemmi H, Kaisho T, Takeuchi O, et al. Small anti-viral compounds activate immune cells via the TLR7 MyD88-dependent signaling pathway. Nature Immunology, 2002, 3(2): 196-200. 2. Harrison CJ, Jenski L, Voychehovski T, et al. Modification of immunological responses and clinical disease during topical R-837 treatment of genital HSV-2 infection. Antiviral Research, 1988, 10(4-5): 209-223. |
|
Quality Control & MSDS
- View current batch:
Chemical structure
